Tyra Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	59.01	252.21	302.43	15.47	0.11
Short-Term Investments	145.46	0	0	0	0
Cash & Cash Equivalents	204.47	252.21	302.43	15.47	0.11
Cash Growth	-18.93%	-16.60%	1855.29%	14221.30%	-
Other Current Assets	7.2	5.08	1.63	-0.19	0.02
Total Current Assets	211.67	257.29	304.06	15.28	0.13
Property, Plant & Equipment	8.15	3.54	2.09	0.47	0.28
Other Long-Term Assets	6.03	5.35	0.56	0.26	0.13
Total Long-Term Assets	14.19	8.89	2.64	0.73	0.4
Total Assets	225.86	266.18	306.7	16.01	0.53
Accounts Payable	4.66	1.15	0.6	0.66	0.33
Current Debt	0.28	0.14	0.2	0.14	4.46
Other Current Liabilities	10.39	4.42	2.82	1.05	0.36
Total Current Liabilities	15.33	5.7	3.62	1.86	5.16
Long-Term Debt	6.22	2.48	0.98	0	0.11
Other Long-Term Liabilities	0.05	0.17	0.37	0.14	0
Total Long-Term Liabilities	6.26	2.65	1.35	0.14	0.11
Total Liabilities	21.6	8.35	4.96	2	5.27
Total Debt	6.5	2.62	1.18	0.14	4.58
Debt Growth	147.75%	121.64%	733.10%	-96.90%	-
Retained Earnings	-164.83	-95.7	-40.37	-14.08	-4.74
Comprehensive Income	0.38	0	0	0	0
Shareholders' Equity	204.26	257.83	301.74	-13.64	-4.74
Net Cash / Debt	197.97	249.59	301.24	15.33	-4.47
Net Cash / Debt Growth	-20.68%	-17.15%	1865.69%	-	-
Net Cash Per Share	4.64	5.96	21.86	9.94	-4.38
Working Capital	196.34	251.59	300.44	13.42	-5.03
Book Value Per Share	4.78	6.16	21.90	-8.84	-4.65

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).